We have assessed five high-throughput systems for the measurement of glycated haemoglobin and have reviewed published evaluations of individual analysers. All systems offered better precision than a widely used electroendosmosis method. The low pressure chromatography and immunoassay systems demonstrated greater between-batch imprecision than the high performance liquid chromatography analysers, the latter achieving the proposed analytical goal of between-batch coefficients of variation less than 5OJo. Agreement between all systems measuring HhA. was good but there was variability amongst observed HbA lc values. The systems were also assessed for their quality of chromatographic separation, simplicity of operation, flexibility, cost and potential for interference by other haemoglobins.
Haemoglobin in its glycated form is measured as total glycated haemoglobin (GHb), as N-terminal glycated haemoglobin A (HbA 1 ) or its major subfraction, HbA l c ' The main use of glycated haemoglobin measurements is to assess long-term glycaemic control in the management of diabetes mellitus.l-? It is difficult to obtain a reliable estimate of mean blood glucose concentrations in insulin-dependent diabetes from the measurement of random glucose concentrations because of unpredictable fluctuations in this parameter. Glycated haemoglobin gives an objective assessment of the integrated mean blood glucose concentration over the preceding six to eight weeks, providing clinical information not otherwise available;' Consequently, it is an important factor when assessing the appropriate insulin dose. Knowledge by clinicians of the HbA l c result has been shown to lead to a lower mean HbA l c concentration and fewer hospitalizations for hypo-or hyperglycaemia when compared with a matched group of patients for whom the HbA l c results were withheld." The benefits were greatest in those patients with the poorest initial control of their diabetes. In non-insulin-dependent diabetics receiving dietary therapy or oral hypo-Correspondence, Dr R P Taylor. 494 glycaemic agents the value of the information gained from glycated haemoglobin measurement remains debatable because fasting plasma glucose correlates well with pre-or post-prandial glucose concentrations through the day. 1 The recognition of the clinical value of glycated haemoglobin assays in insulin-dependent diabetes and' their widening application to patients such as those receiving diabetic care from their general practitioners has created an increasingly heavy workload. The lack of a suitable calibrant and the different principles of measurement employed have resulted in considerable bias differences between methods, and for some non-robust methods substantial inter-laboratory differences have been observed.' For many laboratories some degree of automation is essential and speed of analysis is an additional important consideration, particularly with the increasing interest in analysing patients' samples during their outpatient clinic visits. Recent years have seen improved electrophoretic methods.s" high-performance liquid chromatography (HPLC) using ion-exchange columns." low pressure chromatography, and immunoassay.'? Application of these principles in the latest glycated haemoglobin systems allows improved automation, speed, high sample capacity, simplicity of operation and varying degrees of freedom from interference by other haemoglobin species. As no one method is regarded as the method of choice, laboratories have to decide individually!' on the best approach according to their own requirements for workload, speed and test repertoire.
The aim of this paper is to discuss these factors against the background of new methodology and to determine.the extent to which the systems now available meet the growing demands made upon service laboratories. We have assessed the liquid chromatography and immunoassay systems offering the highest speed and degree of automation and have compared the findings with previously published reports and with information provided by the manufacturer.
ANALYTICAL SYSTEMS
The five systems examined were the Glycomat, Diamat, Hi-Auto 8121 and Shimadzu liquid chromatography analysers and the Novoclone immunoassay system. A new system available but not included in this assessment is the MDMS, a modular manual or semi-automated HP.LC system from Bio-Rad optimized for HbA l c and similar in concept to Shimadzu. The two newer electrophoretic systems, Helena REP (Helena Laboratories (UK) Ltd, Gateshead, UK) and Paragon Diatrac HbA lc (Beckman Instruments (UK) Ltd, High Wycombe, UK), which offer some improvements on established electrophoretic methods but do not have the combination of high throughput and automation offered by the others, were also not assessed. Further details of these systems may be found in the literature.s-i-" Liquid chromatography (LC) methods One low pressure and several high pressure cation exchange resin systems are available. All are highly automated but with one exception require the predilution of the sample to achieve both haemolysis and removal of the labile aldimine fraction.
Low pressure system
In the Glycomat (manufacturer Drew Scientific, Chiswick, London, UK; distributor Ciba Corning Diagnostics, Halstead, UK) haemoglobin is separated from its glycated forms on disposable minicolumns. Each column can perform more than 150 separations using a binary gradient. There are three additional applications for the instrument which detect and in some cases quantify abnormal haemoglobins, They involve the use of a single alternative column with one of the three gradient profiles. Haemoglobin A 2 can be estimated alone or with haemoglobin F (HbF) and S (HbS)
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and there is a rapid screening protocol for HbS.
High pressure systems Diamat (manufacturer Toya-Soda, Tokyo, Japan; distributor Bio-Rad Laboratories, Hemel Hempstead, UK) uses a tertiary gradient to separate the fractions. With a different column and eluants the instrument can be used to quantify HbA 2 and detect a wider range of abnormal haemoglobins in addition to the HbS, C, F and E detectable with the glycated haemoglobin protocol. Hi-Auto Alc, HA 8121 (manufacturer Kyoto Daiichi, Kagaku, Kyoto, Japan; distributor, Biomen Limited, Croydon, UK) is the most recent GHb analyser from Kyoto Daiichi. It is at present unique in its ability to dilute, haemolyse and remove the labile fraction of HbA 1c within the instrument. This is achieved by incubation of the sample in a thermal-jacketed loop for 2 min at 48°C in the presence of tetrapolyphosphate at pH 6. 12 This instrument is dedicated to the estimation of HbA l and HbA l c '
The Shimadzu HPLC Haemoglobin System (manufacturer Shimadzu Corporation, Tokyo, Japan; distributor Dyson Instruments Ltd, Houghton-le-Spring, UK) is based on the established LC-6A modular HPLC system and unlike the other two HPLC systems it uses a binary gradient.
Immunoassay
Novoclone HbA l c (Dako Diagnostics Ltd, Ely, UK-formerly Novo Nordisk) is an enzymelinked immunoassay (ELISA) kit based on a monoclonal antibody specific to the N-terminal of the haemoglobin {j-chain with glucose attached in its stable, ketoamine form. Erythrocytes are washed, lysed and incubated for 10 min at 15°to 30°C. The resulting haemolysates are mixed with coating buffer and loaded immediately into microtitre plate wells where the haemoglobin species bind directly to the polystyrene surface. Unbound material is removed by washing and antibody conjugated to horseradish peroxidase is added. Further washing removes excess conjugate and HbA 1c is estimated by measuring the remaining peroxidase activity after timed reaction with o-phenylenediamine using a microtitre plate reader. Results are expressed as percentage HbA 1c from a standard curve derived from the four calibrants analysed in duplicate on each plate. Partial automation of the procedure is now possible using the Tecan 5032 sample processor and washing system (Tecan UK Ltd, Reading, UK) but this was not available at the time of assessment.
METHOD
Comparisons of analytical performance were made between the five systems and also with the Glytrac electroendosmosis method (Ciba Corning Diagnostics, Halstead, UK). Analyses were performed on routine clinical samples received for glycated haemoglobin estimation according to the manufacturer's instructions and using reagents supplied by the manufacturer. Within-and between-batch imprecisions were determined and the effects of potentially interfering haemoglobin species were assessed. Some instruments wer~only available for a short time and as a result It was necessary to determine the between-batch imprecision on duplicate samples analysed in two batches. Inter-instrument bias was assessed by analysis of samples on two or more analysers. In addition the particular characteristics of each system were investigated with emphasis on flexibility and simplicity of operation in routine use. It is on these factors that the selection of a system is likely to be made if precision and accuracy are adequate.
RESULTS AND DISCUSSION

Imprecision
Within-and between-batch coefficients of variation (CV) of 50/0 have been regarded as attainable and therefore suggested as desirable targets for routine HbA 1c assay, but this quality goal is empiri.ca~. 13 On the more objective basis of observed withinsubject variation and modelling of strategies for use of HbA lc in clinical practice it has been suggested recently!" that the maximum acceptable CV should be 5% and that the optimal CV approaches 2%. Table 1 shows the within-and between-batch imprecision data. They are in broad agreement with those reported by other laboratories, as is shown in the imprecision profiles compiled from these results and the reported findings of others ( Fig. 1 ). All but the Glycomat, Novoclone and Glytrac showed between-batch imprecision which satisfied the proposed analytical goal of 5%. The Glycomat demonstrated excellent within-batch imprecision, the poor between-batch performance being attributed by the supplier to a particular column operating below specification. As the Glycomat columns are changed every 150 samples there may be insufficient opportunity within the short life of each column to accumulate enough quality control data to demonstrate any deficiency in performance.
The Novoclone data were obtained with a manual protocol, which has nine separate pipetting or washing stages. It is possible that automation of these would generate an improvement. The imprecision was relatively high and variable, with similar ranges for within-and between-batch. This can be explained by the large number of manipulations and the possibilities for variation in the assay conditions in wells within an individual plate, with the extent of this variability being similar to the variation between plates. The precision profiles show no clear differences in imprecision between HbA! and HbA lc for any of the analysers where data for both are available. Decisions regarding which analyte should be reported will therefore depend on other factors.
Accuracy
The approaches to calibration differ between the instruments assessed. The Daiichi HA 8121 and Glycomat calculate results directly from the peak areas for each chromatogram whereas the Shimadzu and Diamat results are calculated by comparison with chromatograms of calibrant samples. In all chromatographic systems the accuracy of results is to some extent dependent upon the quality of separation and the characteristics of the integrator. In the case of the Diamat for example, peak broadening with column age necessitates frequent recalibration using the standard supplied by the manufacturer. For minor calibration adjustments multiplication factors are entered to modify the peak area calculations. In addition the flow rate may require adjustment until the peak elution times for the calibrant sample fall within a range assigned by the manufacturer. In contrast the Daiichi HA 8121 and Glycomat have no routine user adjustments. Data from this evaluation and the published findings of others, showing comparisons with Glytrac and comparisons between the high throughput and other methods, are given in Tables 2 and 3 . The data show an overall broad agreement between those systems capable of measuring HbA I . For HbA!c, however, there is considerable variation, the Diamat giving the highest results and the Novoclone the lowest, with the Shimadzu and HA 8121 values lying between them. These differences are also evident from the manufacturers' reported reference intervals for non-diabetics (Diamat 4· 3-6' I lIJo , n = 131; Novoclone 2· 8-4' 9%, n = 253) and from the findings of other workers. I? The Glycomat results are similar to those of the Diamat. The negative bias of the Novoclone is stated by the manufacturers to be due to the high specificity of the monoclonal antibody. The inter-method bias means that the adoption of HbA lc does not solve the current problem of method-associated clinical decision limits. The question of accuracy and specificity has been confused by Bio-Rad's recent launch of an ELISA method employing the same reagents as the Novoclone assay but recalibrated to give HbA!Cresults that agree with their Diamat analyser. The relative importance of accuracy is likely to depend on the outcome of dialogue with clinical staff regarding their views on the adoption of lower decision limits. Bio-Rad's decision to recalibrate the immunoassay presumably reflects the importance of the clinicians' role. 
Quality of LC separation
Typical chromatograms for each LC system are shown in Fig. 2 . The Diamat shows good resolution between all the minor fractions (Ala' Alb' Ale and F) when operating on its 8 min cycle and a percentage value is given for each fraction. A 5 min separation can be selected which will shorten the column life but should still allow the guaranteed minimum of 1000 separations. .. ""I I. baseline resolution of the minor haemoglobin fractions only between HbA lc and HbAo, with HbA lc only moderately resolved from HbF. Between HbA lc and HbF is the shoulder known as # C. The nature of this material has been investigated" and it is considered to be a subfraction of HbA 1c since on a longer separation it appears as a small peak between stable and labile HbA1c" However, the labile fraction, if not removed, also appears in this position with the recommended gradient. The speed of the HA 8121 enables it to achieve a throughput in excess of all but the very largest workloads but the quality of the chromatographic separation is such that the peaks are incompletely resolved. The authors feel that it would be desirable to have available an alternative gradient programme, similar to that of the Diamat, with a slower but more complete separation. The Shimadzu and Glycomat achieve a good separation of HbA lc from Alb and Ala, which elute together at the beginning of the chromatogram. The Shimadzu resolves HbF and HbA\c moderately well but these fractions coelute on the Glycomat so that in the latter HbF may add significantly to the result. A warning message to this effect is printed on the report if the apparent HbA lc level is above a previously defined percentage.
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Automation
Degree of automation
The main characteristics of each system are described in Table 4 . Despite its rapid sample throughput the Novoclone system in its manual format has many operator-dependent steps. The complexity of the protocol can be largely overcome by running some or all of the steps on a sample processor. The other options for a high degree of automation are the LC systems. Of these, the Daiichi HA 8121 is the only analyser able to haemolyse and remove the labile fraction from the samples during each sample cycle. While this primary sampling facility is undeniably a considerable advantage there are two associated problems. First, the sample racks will hold only a limited range of tube types. Laboratories receiving samples in a variety of different containers may have to transfer some to alternative tubes, with risk of sample transposition. Secondly, paediatric and other low volume specimens are sampled individually either as whole blood or haemolysate from a single 'stat' position which requires manual loading. This becomes time consuming if there are a large number of such samples. It is possible to reset the instrument to accept racks of manually prediluted samples, but these must be run as a separate batch using 'pre-haemolysed' mode. Transfer between modes requires entry of a relatively complex code and the analyser does not have a display to indicate its current mode setting. The HA 8121 must be reset to 'whole blood' mode before primary sampling is resumed. A potentially serious drawback of this arrangement is that the analytical column is likely to be rendered useless if whole blood specimens are inadvertently sampled while the instrument is still set to 'pre-haemolysed' mode. Users are recommended not to transfer between modes but if it is to be avoided the requirements for analysis of paediatric and other low volume samples must be carefully addressed. All other systems accept only prediluted samples but this uniformity of sample presentation minimizes the procedural problems discussed above.
Features of automated systems for glycated haemoglobin estimation
Complexity and flexibility
Laboratories with no experience of HPLC may be deterred by the perceived complexity of the technique but the Diamat and HA 8121, both dedicated instruments, were simple to operate and would be easily assimilated. The Diamat appeared to be the most thoroughly developed and has a clear status display panel. It could be the most suitable for a laboratory unfamiliar with the technique. At the other end of the scale the Shimadzu system was the least well presented. Being a modular rather than integrated system it is without operator alarms and 'self-diagnosis' or 'stat' facilities. It also appeared to have limited technical information and support. However, its design does allow the addition of extra modules if required and alteration of system parameters is easy to perform. Instruments of this type, including Bio-Rad's similarly configured MDMS HhAj, analyser could be the instruments of choice for a laboratory with a moderate HbA lc
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workload and a requirement for other HPLC applications concurrently or at a later date. With the high capital cost of these systems the possibility of an alternative future use would be an advantage. However, when considering multiple applications it should be noted that HPLC systems can require several hours of re-equilibration time between methods in order to achieve reproducible results and the use of the same pump for a variety of eluants can lead to decreased reliability. A laboratory which already has a sample processor may be able to make a considerable capital saving by adapting it to accept the Novoclone method. Conversely, an automated Novoclone system would provide versatile hardware suitable for other commonly performed immunoassays if requirements such as sampling probe configuration were established in advance. This option could be particularly attractive to laboratories with a moderate workload of several analytes such as hormones.
Speed ofanalysis, throughput and sample capacity
Data on sample throughput and run times are shown in Table 4 . The Daiichi HA 8121 has twice the throughput of the other LC systems. This feature, coupled with the ability to analyse whole blood samples directly, makes the HA 8121 the system of choice if 'real time' analysis in a clinic setting is a consideration.P However, even with this speed, it can analyse only 45 samples in a 3 h period, which may be too slow for many diabetic clinics. The Diamat has been shown to perform satisfactorily in a clinic setting!' but even using the 5 min gradient its throughput would be less than that of the HA 8121. 'Stat' specimens are accepted by the Glycomat, Diamat and HA 8121, in each case analysis taking place after completion of the current routine sample.
Only the Diamat offers a cooled sample chamber but it has a capacity of only 48 samples, just less than half the capacity of the other LC systems. This need not be restrictive because the Diamat can analyse 48 samples in under 6· 5 h and therefore a second set of samples can be loaded within the working day. It can store data from up to 96 samples in memory. Of the other analysers with larger non-cooled sample chambers only in the Glycomat did the temperature rise noticeably, since the samples are situated above heat-generating electronic components. As a full load of 100 samples requires over 21 h for analysis there is a possibility of sample deterioration.
The Novoclone has a very high throughput, with one plate of up to 88 specimens being completed in 2 to 2·5 h. Where a sample processor is used individual plates have to be run successively because the instrument is occupied for a large proportion of total assay time.
Capital outlay, running costs and staff time The list price and consumable cost per sample for each system are shown in Table 5 . The HPLC instruments and fully automated Novoclone system with sample processor have broadly similar capital costs, the low pressure Glycomat costing significantly less. Running costs of all the chromatographic systems are dependent on the life of the analytical column which is the major component of reagent costs. They are guaranteed for a certain number of injections and on this basis maximum costs can be calculated. With careful use column life is likely to exceed the guaranteed minimum, with significant reductions in costs. All the chromatographic techniques have maximum running costs similar to the Glytrac method. The Novoclone is the most expensive whether manual or automated, the cost being further increased by the necessity for eight wells of calibrant per plate. However, the manual immunoassay does offer the opportunity for improved precision and specificity and increased sample throughput compared with the Glytrac for a relatively small capital outlay.
Staff costs are a major contributor to the cost of analyses. It is estimated that the implementation of any of the LC systems or the automated immunoassay would reduce by two thirds the operator time to perform the existing workload of up to 150 samples per week. In the case of LC analysers the routine operation could be performed by relatively inexperienced staff although a more senior operator would be responsible for long-term maintenance and supervision. The immunoassay, because of its complexity, would require experienced staff, especially if the assay were to be done manually.
Customer support and reliability The long-term quality of the service which any laboratory can achieve will largely be dictated by the robustness of the assay and the aftersales service provided. As there are few objective criteria available to assess either factor some of the following comments are necessarily subjective.
The Novoclone immunoassay has a long and technically demanding protocol which could give rise to analytical difficulties especially when used manually. Despite some initial problems with the evaluation both manufacturer and distributor of the Glycomat were supportive but the instrument appeared underdeveloped at the time of evaluation. The HA 8121 performed very well at first but subsequently there was a recurring fault which the distributors were slow to rectify. The Bio-Rad personnel were both informative and helpful in support of the Diamat and most problems occurring during the evaluation could be solved using the operator's manual. The Shimadzu system performed well but technical support was limited.
"bAI or "bAle? Various factors support HbA!e as the analyte of choice for assessment of glycaemia in diabetes mellitus. Of the HbA I sub fractions it is the only one to be increased to any great extent by the raised blood glucose levels seen in diabetics-P'! and HbA le appears to be less affected by interference from carbamylation seen in uraemic patients than is the measurement of HbA 1 . 32 Also there is evidence that HbA Ic is more stable on storage, with levels of HbA I rising more rapidly than those of HbA 1e, especially in samples kept at room temperature." However, there remain significant differences in HbA le results between methods which may be due to variable chromatographic behaviour of HbA le subspecies. This is supported by the observation that the HbA Ic peak as seen in the HA 8121 has a shoulder suggesting the presence of subfractions and also by the lower values of the Novoclone immunoassay, claimed to be due to its high specificity. The selection of a method which allows reporting of HbA I or HbA lc could be an advantage because at present neither analyte is clearlypreferable, particularly in view of the intermethod variability of HbA lc' The Novoclone and Shimadzu systems give values for HbA lc only whereas Glytrac measures only total HbA I . The Diamat, Glycomat and HA 8121 report both HbA I and HbA 1c'
Fetal haemoglobin
Blood from normal adults contains up to 0'5% of fetal haemoglobin (HbF). The HbF fraction is often significantly elevated in patients suffering from thalassaemias, in those with structural variants of haemoglobin" and rarely as a result of hereditary persistence of fetal haemoglobin." It is raised to a lesser extent in pregnancy and in a variety of other conditions. Levels of HbF have also been shown to be higher in a proportion of children and adolescents with Type 1 diabetes than in controls and are often in excess of O' 5%. 36, 37 As more precise methods are used and better diabetic control is achieved the variation in HbF becomes more important. Methods capable of measuring glycated haemoglobin with minimal contribution from HbF are therefore desirable particularly where pregnant diabetics, young diabetics and patients with haemoglobinopathies are concerned. The comigration of HbF with HbA I is a considerable disadvantage of the Glytrac and most other electroendosmosis methods. The Diamat, HA 8121 and the Shimadzu systems all achieve acceptable resolution of HbA lc from HbF but in the Glycomat HbA lc and HbF co-elute. The highly specific antibody of the Novoclone assay does not measure HbF.
Methaemoglobin
Methaemoglobin (metHb) forms in whole blood samples on storage and small amounts can be present in some samples which are only a few days old. With the LC methods it is therefore necessary to ensure that metHb does not co-elute with any of the HbA I subfractions. In the Glycomat metHb elutes between HbA lc and HbAo and the separation and integration is such that it is unlikely to interfere. In the Diamat metHb fills the trough between HbA lc and HbAo. As the baseline is drawn from trough to trough the effect is to subtract a greater amount from the area of both peaks. The amount subtracted will be a relatively larger proportion of the HbA!c peak and may produce a lower result indicating that early analysis of samples is particularly important Methods for glycated haemoglobin 503
with this system. MetHb is not seen on HA 8121 chromatograms and it was not possible to ascertain its position experimentally. Similarly, with the Shimadzu the position of metHb on the chromatogram is not clear. It is said by the manufacturers not to interfere, but they advise analysis of samples while less than one week old. The specificity of the antibody used in the Novoclone immunoassay should prevent any interference from metHb.
Abnormal haemoglobins
In some laboratories the number of samples received from diabetic patients with abnormal haemoglobins is low but in areas with a large immigrant population samples of this type may constitute a significant proportion of the workload. In such patients interpretation of results is complicated by the shortened erythrocyte lifespan reducing the apparent level of glycation, the presence of HbF which interferes in some methods and the complete absence of HbA (and therefore of HbA 1 ) in homozygotes for the structural variants. None of the systems examined here provides the ideal answer to the problem of monitoring glycaemic control in the presence of all types of haemoglobinopathy. The Diamat, in its standard format, is a highly effective instrument for recognizing structural variants" and with both this and the Glycomat it is possible to express HbA lc as a percentage of HbAo in heterozygotes for the most common structural variants C and S using the basic gradient. In order for this approach to be of value for long-term monitoring of affected individuals relative amounts of HbA and the variant form have to be assumed to be constant. The immunoassay measures the absolute amount of HbA 1c, but in patients with structural variants this will reflect the level of HbA, which may be low or absent. Good agreement of the immunoassay with the Diamat is only seen where the N-terminal is unaltered."? HbA lc by immunoassay could be used to monitor individual known affected diabetics but a diabetic with an unknown haemoglobinopathy may well give a falsely low (apparently normal) level in the presence of poor control. It could be argued that such results cannot be interpreted without knowledge of haemoglobin status. With the Shimadzu and HA 8121 abnormal haemoglobins are eluted with or shortly after HhA, and the only indication of an abnormality will be, in most cases, an unexpectedly low HbA lc (as a percentage of apparent HbA o ) with the implications discussed above. On the Shimadzu HbS and HbC have such long retention times that they appear in the chromatogram of the following sample. The Shimadzu does have the option to use an extended gradient to resolve the commoner forms.
With all methods the importance of investigation of unexpectedly low results and examination of individual chromatograms for unusual peaks cannot be overstated. The best approach to providing a service for these patients would be to measure total GHb by affinity chromatography. This gives a measure of total glycation of all haemoglobins present as a percentage of the total in the individual at that time. Different structural variants may prove to be glycated to different degrees and the relative amounts of haemoglobin types in heterozygotes may vary but these factors should have only a minor effect. This approach would rely for its success on affected patients being identified by the laboratory or the requesting clinician.
CONCLUSIONS
We have assessed both the quality of analytical performance and the many practical features of each system. Precision was considered to be the most important factor, with the three HPLC systems offering the best between-batch precision and coming very close to satisfying even the most stringent analytical goals for GHb. The Novoclone system in manual format and Glycomat appear to suffer from poorer performance but are better than electroendosmosis both in terms of precision and sample throughput. The true capabilities of the Novoclone system will be known when the remaining steps of its complex protocol have been successfully automated. There is very good agreement between systems measuring HbA I . For HbA 1e , however, which is probably the preferred analyte on scientific grounds, the difficulties of calibration and the remaining problems with chromatographic separation can result in large differences between the various instruments. This has implications for clinical decision limits. Novoclone offers by far the most rapid sample throughput which would suit it to very high workloads. The versatility of the sample processor necessary for its automation enables it to analyse smaller numbers of HbA 1e samples alongside other assays. Similarly, the versatility of the Shimadzu and MDMS systems may be important for laboratories wishing to acquire a flexible HPLC system, but their relative complexity must be considered. The HA 8121 is the fastest LC analyser, and has primary sampling and automatic haemolysis, features not shared by the other systems. These advantages coupled with its speed of analysis make it the instrument of choice for near patient testing. The Diamat offers good quality chromatography and rapid analysis, is easy to operate and has a good record for reliability. The Glycomat has low capital and reagent costs but is the least precise of the systems examined and does not resolve HbF and HbA 1e • The questions of specificity, interfering peaks and the location of haemoglobin variants on chromatograms are more minor considerations but may be of local importance because of the particular population served.
